RxDoctor Payments Data

Clara Kalil, MD

General Practice · Quebradillas, PRNPI 1528218971

Payments from drug & device makers

$403in general payments, 2019–2025

Across 6 payments — averaging $67.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$124
  • E.r. Squibb & Sons, L.L.C.$121
  • Amgen$102
  • GSK$35
  • Pfizer$20

What the payments were for

  • Food & beverage$403100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson1$124
E.r. Squibb & Sons, L.L.C.1$121
Amgen1$102
GSK2$35
Pfizer1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$403 in reported general payments places this provider in the 70th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$671,790
Medicare patients
670
Services billed
23,144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide114$156,515
EliquisApixaban90$96,284
JanuviaSitagliptin Phosphate90$75,400
XareltoRivaroxaban27$24,974
JardianceEmpagliflozin16$24,491
FarxigaDapagliflozin Propanediol21$20,606
MyrbetriqMirabegron17$18,223
Lantus SolostarInsulin Glargine,hum.Rec.Anlog71$11,100
Rosuvastatin Calcium603$8,878
Levothyroxine Sodium661$6,019
Repatha SyringeEvolocumab11$5,756
Atorvastatin Calcium448$4,667
Losartan Potassium401$4,567
SynthroidLevothyroxine Sodium77$3,854
Gabapentin276$3,780

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$20$97,713101 claims
Johnson & JohnsonXarelto$124$24,97427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in Quebradillas

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →